Fig 3.tif (575.55 kB)
Characterization of chimeric HPV16L1-17RG1 and 5L1-17RG1 VLP by ELISA.
figure
posted on 2017-01-05, 18:57 authored by Bettina Huber, Christina Schellenbacher, Saeed Shafti-Keramat, Christoph Jindra, Neil Christensen, Reinhard Kirnbauer(A) HPV16L1-17RG1 VLP were compared to wt HPV16 L1 VLP under native conditions using neutralizing mAb H16.V5 and H16.E70, and non-neutralizing mAb Camvir-1. (B) Serial dilutions of antisera raised against HPV16L1-17RG1 or HPV5L1-17RG1 were analyzed in triplicates by HPV17RG1 peptide ELISA. Serum titers are reported for OD values greater than the mean OD of pre-immune sera plus 3 standard deviations (SD).
History
Usage metrics
Categories
Keywords
HPV 4 challengechimeric proteins self-assembledcapsid proteinsnon-melanoma skin cancerHPV 16 L 1 VLPmurine PsV challenge modelVLP-raised NZW rabbit12 novel beta PsV typesmucosal HPV infectionsHPV 16L VLPRG 1 homologRG 1-based VLPChimeric L 2-Based Virus-Like ParticleHPV 5L VLP cross-protectedHPV 5L aa 53-72 epitopecutaneous HPV typesHPV 16 L 2 cross-neutralization epitope RG 1L 2 peptideHPV 1L VLP cross-protectedspecies beta HPV18 L 1 VLP scaffoldsELISAHPV 17 RG 1 epitopecutaneous HPV 4 RG 1 homologDE surface loopsExperimental papillomavirus vaccinesgeneration vaccine candidatestarget cutaneous HPV infectionstarget cutaneous HPVLicensed HPV vaccinestype-common neutralization epitopesVaccines Targeting Cutaneous Human PapillomavirusesL 1 fusion proteinstarget heterologous HPVNMSCL 2-based pseudovirion
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC